EML4 and melanoma: Analogously to METi and EGFRi, the EML4-ALK translocation-based cellular model H3211 was exposed to the ALK inhibitor crizotinib (ALKi) and the BRAF V600E-addicted melanoma cell line G361 to the BRAF inhibitor (BRAFi) vemurafenib (Fig. 4A, B).